Avalo Therapeutics (NASDAQ:AVTX) Cut to Sell at Wall Street Zen

by · The Cerbat Gem

Wall Street Zen lowered shares of Avalo Therapeutics (NASDAQ:AVTX – Free Report) from a hold rating to a sell rating in a research note released on Saturday morning.

Several other analysts have also recently commented on the company. Citizens Jmp dropped their price target on Avalo Therapeutics from $62.00 to $55.00 and set a “market outperform” rating for the company in a research report on Thursday, May 14th. Cantor Fitzgerald restated an “overweight” rating on shares of Avalo Therapeutics in a report on Friday, July 24th. Bank of America started coverage on shares of Avalo Therapeutics in a research note on Friday, June 12th. They set a “buy” rating and a $35.00 target price on the stock. Mizuho increased their target price on shares of Avalo Therapeutics from $39.00 to $45.00 and gave the company an “outperform” rating in a research report on Thursday, May 14th. Finally, Leerink Partners initiated coverage on shares of Avalo Therapeutics in a research report on Monday, July 6th. They issued an “outperform” rating and a $38.00 target price for the company. Thirteen investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Avalo Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $45.10.

View Our Latest Research Report on Avalo Therapeutics

Avalo Therapeutics Trading Up 7.9%

AVTX stock opened at $19.77 on Friday. Avalo Therapeutics has a 12-month low of $8.29 and a 12-month high of $24.27. The stock has a market cap of $1.06 billion, a price-to-earnings ratio of -4.52 and a beta of 0.80. The business’s 50-day moving average is $17.34 and its 200 day moving average is $16.33.

Avalo Therapeutics (NASDAQ:AVTX – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.83) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.25). As a group, equities analysts forecast that Avalo Therapeutics will post -2.58 EPS for the current fiscal year.

Insider Buying and Selling

In other Avalo Therapeutics news, insider Mittie Doyle sold 1,450 shares of the business’s stock in a transaction dated Tuesday, June 23rd. The shares were sold at an average price of $18.00, for a total value of $26,100.00. Following the transaction, the insider directly owned 51,776 shares in the company, valued at $931,968. The trade was a 2.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.46% of the stock is owned by company insiders.

Institutional Investors Weigh In On Avalo Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP acquired a new position in shares of Avalo Therapeutics in the 3rd quarter valued at $143,000. Boothbay Fund Management LLC acquired a new stake in shares of Avalo Therapeutics during the 2nd quarter worth about $56,000. AlphaCentric Advisors LLC purchased a new stake in Avalo Therapeutics in the 1st quarter valued at about $174,000. Jump Financial LLC acquired a new position in Avalo Therapeutics in the fourth quarter valued at about $238,000. Finally, Persistent Asset Partners Ltd purchased a new position in Avalo Therapeutics during the fourth quarter worth about $274,000. Institutional investors and hedge funds own 87.06% of the company’s stock.

About Avalo Therapeutics

(Get Free Report)

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.

Featured Articles